Industry Attorneys Criticize FDA’s Emerging Signals Draft Guidance
This article was originally published in The Gray Sheet
Executive Summary
A recent draft guidance from FDA establishing a process for issuing early public warnings of possible safety risks linked to devices is raising the hackles of industry attorneys and advocates who say the warnings could confuse patients, lead them to avoid appropriate use of devices and increase the likelihood of frivolous lawsuits.
You may also be interested in...
FDA Drafts Plan To Publicize 'Emerging Signals' Of Device Risks
In a draft guidance, FDA explains how it plans to communicate signs of postmarket device risks before it has performed a full analysis or developed specific recommendations. Public health advocates say it is a positive move to get ahead of potential safety problems early. The agency is seeking comment from companies on whether it needs to consult with firms prior to releasing information on emerging signals about their devices.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.